{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T06:19:36Z","timestamp":1792909176474,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to investigate the mortality rate and identify the predictors of death in patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis were recruited from the Neurology Department of the First Hospital of Jilin University from March 2015 to November 2021. The primary outcome variable was a binary variable of death vs. survival. The potential risk factors for mortality were evaluated. The mortality rates were determined, and the independent predictors of death were identified using multivariable logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 100 hospitalized patients with anti-NMDAR, anti-LGI1, or anti-GABABR encephalitis were included in the final analysis. Fifteen patients (15%) died during a median follow-up period of 18 months. The mortality rates were 10% for anti-NMDAR encephalitis, 2.8% for anti-LGI1 encephalitis, and 41.7% for anti-GABABR encephalitis. The multivariable analysis results showed that older age at onset [adjusted odds ratio (OR) = 1.017, 95% confidence interval (CI) = 1.009\u20131.136; <jats:italic>p<\/jats:italic> = 0.023] was independently associated with an increased risk of death. Antibody type was also associated with mortality. Patients with anti-GABABR encephalitis had 13.458-fold greater odds of dying than patients with anti-LGI1 encephalitis (adjusted OR = 13.458, 95% CI = 1.270\u2013142.631; <jats:italic>p<\/jats:italic> = 0.031).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The general mortality rate of anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis was 15%. Age at onset and type of autoimmune encephalitis antibody were independent predictors of death in these patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.845365","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T04:55:56Z","timestamp":1646628956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis"],"prefix":"10.3389","volume":"13","author":[{"given":"Rui","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2017.08.012","article-title":"Autoimmune Epilepsies","volume":"24","author":"Yeshokumar","year":"2017","journal-title":"Semin Pediatr Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.08.009","article-title":"An Evolving Redefinition of Autoimmune Encephalitis","volume":"18","author":"Esposito","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00280","article-title":"Clinical and Electroencephalographic Features of the Seizures in Neuronal Surface Antibody-Associated Autoimmune Encephalitis","volume":"11","author":"Wang","year":"2020","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01136","article-title":"Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1115720","article-title":"Immune Therapy in Autoimmune Encephalitis: A Systematic Review","volume":"15","author":"Nosadini","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000909","article-title":"Management of Autoimmune Encephalitis","volume":"34","author":"Bien","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and Prognostic Factors for Long-Term Outcome in Patients With Anti-NMDA Receptor Encephalitis: An Observational Cohort Study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822cfc6b","article-title":"Analysis of Relapses in Anti-NMDAR Encephalitis","volume":"77","author":"Gabilondo","year":"2011","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3188","article-title":"Use and Safety of Immunotherapeutic Management of N-Methyl-D-Aspartate Receptor Antibody Encephalitis: A Meta-Analysis","volume":"78","author":"Nosadini","year":"2021","journal-title":"JAMA Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01030","article-title":"Encephalitis With Antibodies Against the GABAB Receptor: High Mortality and Risk Factors","volume":"10","author":"Lin","year":"2019","journal-title":"Front Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/ane.12723","article-title":"Risk Factors for Mortality in Patients With Anti-NMDA Receptor Encephalitis","volume":"136","author":"Chi","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a4a49c","article-title":"Late-Onset Anti-NMDA Receptor Encephalitis","volume":"81","author":"Titulaer","year":"2013","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-016-0370-7","article-title":"Autoimmune Encephalitis at the Neurological Intensive Care Unit: Etiologies, Reasons for Admission and Survival","volume":"27","author":"Harutyunyan","year":"2017","journal-title":"Neurocrit Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A Clinical Approach to Diagnosis of Autoimmune Encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13121","article-title":"A Definition and Classification of Status Epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51137","article-title":"Seizures and Risk of Epilepsy in Anti-NMDAR, Anti-LGI1, and Anti-GABAB R Encephalitis","volume":"7","author":"Shen","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of Seizure Treatment in Anti-LGI1, Anti-NMDAR, and Anti-GABABR Encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1212\/NXI.0000000000000514","article-title":"Management and Prognostic Markers in Patients With Autoimmune Encephalitis Requiring ICU Treatment","volume":"6","author":"Schubert","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) Receptor in Limbic Encephalitis With Seizures: Case Series and Characterisation of the Antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00415-018-9132-0","article-title":"Isolated Seizures are a Common Early Feature of Paraneoplastic Anti-GABAB Receptor Encephalitis","volume":"266","author":"Maureille","year":"2019","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 Encephalitis: Clinical Syndrome and Long-Term Follow-Up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000958","article-title":"Long-Term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis: A Cohort Study in Western China","volume":"8","author":"Gong","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00835","article-title":"Risk Factors for Intensive Care Unit Admission in Patients With Autoimmune Encephalitis","volume":"8","author":"Harutyunyan","year":"2017","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1212\/WNL.0b013e3182a2cc6d","article-title":"Predictors of Outcome in Acute Encephalitis","volume":"81","author":"Thakur","year":"2013","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201603-0507OC","article-title":"Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care","volume":"195","author":"de Montmollin","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12911","article-title":"Anti-NMDA Receptor Encephalitis: Clinical Characteristics, Predictors of Outcome and the Knowledge Gap in Southwest China","volume":"23","author":"Wang","year":"2016","journal-title":"Eur J Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-018-0536-6","article-title":"Clinical Characteristics and Prognosis of Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis Patients","volume":"29","author":"Zhang","year":"2018","journal-title":"Neurocrit Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-012-0351-0","article-title":"Anti-NMDAR Encephalitis: A New, Severe and Challenging Enduring Entity","volume":"22","author":"van de Riet","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB Receptor Antibodies: Novel Findings in a New Case Series of 20 Patients","volume":"81","author":"Hoftberger","year":"2013","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00025-X","article-title":"Inappropriate Use of Bivariable Analysis to Screen Risk Factors for Use in Multivariable Analysis","volume":"49","author":"Sun","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41512-020-00074-3","article-title":"State of the Art in Selection of Variables and Functional Forms in Multivariable Analysis-Outstanding Issues","volume":"4","author":"Sauerbrei","year":"2020","journal-title":"Diagn Progn Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.845365\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T04:55:58Z","timestamp":1646628958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.845365\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.845365"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.845365","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"article-number":"845365"}}